The standard view says neuroplasticity shuts down months after spinal cord injury. This is wrong. The spinal cord can still sprout axons and rewire circuits years later. The problem is BDNF levels crash in chronic SCI, and without this growth signal, circuits go dormant.

The evidence is surprisingly clear. Even in patients injured decades ago, the anatomical substrate for plasticity remains intact. You can see corticospinal sprouting when you stimulate the cord. Synaptic connections can strengthen with training. The circuits are there, just stuck in low-power mode.

Several drug approaches can restore BDNF signaling:

TrkB Agonists

7,8-dihydroxyflavone crosses the blood-brain barrier and activates the BDNF receptor directly. Its pro-drug R13 has better pharmacokinetics and is moving into trials. TrkB allosteric modulators from AstraZeneca and others boost the response to whatever BDNF is already present—useful since simply injecting BDNF does not work well (poor diffusion, short half-life).

HDAC Inhibitors

Drugs like vorinostat and valproic acid were developed for cancer but increase BDNF expression by altering chromatin structure. This creates a more permissive transcriptional environment for plasticity genes. The mechanism is different from direct receptor activation but the outcome—more BDNF signaling—is the same.

The Critical Synergy

Drugs alone will not do it. BDNF primes neurons for plasticity, but structural change only happens when those neurons fire during specific tasks. This is where most pharmacology studies fail: they test compounds in isolation without the activity-dependent component.

The combination approach—drug plus intensive rehabilitation—is what matters. BDNF creates the permissive state; training sculpts which circuits get strengthened. Studies combining HDAC inhibitors with locomotor training show more corticospinal sprouting than training alone. The pharmacology enables the plasticity; the rehabilitation directs it.

The Reality Check

This will not regrow axons across the lesion site. Severed connections stay severed. But most chronic SCI patients (ASIA C/D) have spared tissue. Strengthening those residual pathways and promoting compensatory sprouting can produce real functional gains—better hand control, improved trunk stability, assisted walking.

Testable Prediction

By 2028, a Phase II trial will show measurable functional improvement in chronic SCI patients (>1 year post-injury) using a TrkB agonist or HDAC inhibitor combined with intensive activity-based training. The effect size will be modest but clinically meaningful—something conventional rehab almost never achieves at this stage.

The plasticity window does not close. It just needs the right key to unlock it.

Research synthesis via Aubrai.